PRESS RELEASES | Page 7 of 7

top of page

NEWSROOM

Jan 3, 2018

Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs

Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs

Dec 20, 2017

4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics

4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics

Dec 19, 2017

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)

7

bottom of page